U.S. stocks traded mixed midway through trading, with the Dow Jones index dipping more than 150 points on Tuesday.The Dow traded down 0.35% to 44,249.09 while the NASDAQ gained 0.07% to 20,427.63. The S&P 500 also fell, dropping, 0.03% to 6,228.39.Check This Out: Top 2 Industrials Stocks You May Want To Dump This QuarterLeading and Lagging SectorsEnergy shares jumped by 2.1% on Tuesday.In trading on Tuesday, utilities stocks dipped by 1.9%.Top HeadlineThe US Manheim Used Vehicle Value Index increased 1.6% m ...

Market Overview - U.S. stocks experienced a decline, with the Dow Jones index falling over 400 points, down 1% to 44,379.69, NASDAQ down 0.85% to 20,426.99, and S&P 500 down 0.39% to 6,255.16 [1] - In commodities, oil increased by 0.7% to $67.44, while gold decreased by 0.5% to $3,325.80, silver fell 0.8% to $36.795, and copper dropped 2.7% to $5.0025 [5] Company News - Cogent Biosciences, Inc. announced positive topline results from Part 2 of the SUMMIT trial for bezuclastinib, showing significant improvements across primary and key secondary endpoints [2] - Mustang Bio, Inc. shares surged 319% to $4.99 after receiving FDA Orphan Drug Designation for MB-101 in astrocytomas and glioblastoma [9] - Artelo Biosciences, Inc. saw a 79% increase in shares to $17.98 following preclinical efficacy results with ART12.11 in a stress-induced depression model [9] - LogProstyle Inc. shares rose 155% to $2.08 after reporting year-over-year financial growth for FY25 [9] - Core Scientific, Inc. shares dropped 21% to $14.21 after CoreWeave announced plans to acquire the company in an all-stock deal [9] - Jasper Therapeutics, Inc. shares fell 51% to $3.2964 after reporting an 89% response rate in its Urticaria study and the decision to halt the program [9] - Apogee Therapeutics, Inc. shares decreased by 16% to $40.03 following the release of 16-week data from Part A of the Phase 2 APEX clinical trial for APG777 [9] Regional Market Performance - European shares showed positive movement, with the eurozone's STOXX 600 rising 0.43%, Spain's IBEX 35 Index up 0.43%, London's FTSE 100 gaining 0.01%, Germany's DAX 40 increasing by 1%, and France's CAC 40 up 0.39% [6] - Asian markets closed mixed, with Japan's Nikkei down 0.56%, Hong Kong's Hang Seng down 0.12%, while China's Shanghai Composite gained 0.02% and India's BSE Sensex increased by 0.01% [7]

Summary of Apogee Therapeutics Conference Call Company Overview - **Company**: Apogee Therapeutics - **Focus**: Development of APG-777 for atopic dermatitis Key Industry Insights - **Market Potential**: The atopic dermatitis market is projected to be worth $50 billion, with APG-777 positioned to potentially transform treatment paradigms [doc id='9'][doc id='33']. Core Points and Arguments 1. **Phase II APeX Study Results**: - APG-777 met or exceeded all key objectives in the Phase II APeX study for atopic dermatitis, demonstrating significant efficacy and a favorable safety profile [doc id='4'][doc id='15]. - 66.9% of patients achieved an EZ-75 response by week sixteen, surpassing results from existing treatments like Dupixent [doc id='15'][doc id='72']. 2. **Dosing and Administration**: - APG-777's induction regimen requires only four dosing days compared to nine for competitors, representing over a 50% reduction in injection days [doc id='14']. - The potential for maintenance dosing every three to six months could lead to 70-90% fewer injections compared to current standards [doc id='26']. 3. **Efficacy Metrics**: - The study showed a greater than 70% absolute percent change from baseline in EASI scores, with rapid lesion reduction observed as early as week two [doc id='15']. - Statistically significant improvements in itch relief were noted, with over 50% decrease from baseline at week sixteen [doc id='17']. 4. **Safety Profile**: - APG-777 demonstrated a promising safety profile, with lower rates of treatment-emergent adverse events compared to placebo [doc id='21']. - No injection site reactions were reported, enhancing the drug's appeal for patients [doc id='23']. 5. **Future Development Plans**: - Multiple data readouts are expected in the coming quarters, including maintenance data and results from the accelerated Part B of the APeX study [doc id='5'][doc id='29']. - Plans to initiate Phase III studies next year, contingent on regulatory alignment [doc id='32']. 6. **Market Positioning**: - APG-777 is expected to be a market leader, with 94% of patients preferring it over existing options if efficacy is equal [doc id='71']. - The company aims to establish APG-777 as a first-line biologic treatment for atopic dermatitis [doc id='73']. Additional Important Insights - **Combination Studies**: Ongoing studies are testing APG-777 in combination with IL-13 and OX40 ligand against Dupixent, which could further differentiate the product in the market [doc id='11'][doc id='44']. - **Regulatory Considerations**: The company is preparing for potential regulatory filings in early 2029, following Phase III trials [doc id='98']. - **Patient and Physician Preferences**: There is a strong demand for fewer injections and improved efficacy, which APG-777 aims to address [doc id='26'][doc id='72']. This summary encapsulates the key points discussed during the conference call, highlighting the promising results of APG-777 and its potential impact on the atopic dermatitis market.

Core Insights - Apogee Therapeutics announced positive results from the Phase 2 APEX clinical trial of APG777, demonstrating significant efficacy in treating moderate-to-severe atopic dermatitis [2][3][4] Group 1: Trial Results - APEX Part A met all primary and key secondary endpoints, achieving a 71.0% decrease in Eczema Area Severity Index (EASI) from baseline at Week 16 [1][9] - APG777 showed an EASI-75 response rate of 66.9%, which is the highest reported for any biologic in a global study, with a placebo-adjusted rate of 42.5% [1][3][9] - The trial included 123 adult patients, randomized 2:1 to receive APG777 or placebo, with a dosing regimen of 720mg at Weeks 0 and 2, followed by 360mg at Weeks 4 and 12 [4][9] Group 2: Safety and Tolerability - APG777 was well tolerated, with a safety profile consistent with other agents in its class, and serious treatment-emergent adverse events (TEAEs) were rare at 1.2% compared to 2.4% in the placebo group [1][9] - The discontinuation rate due to adverse events was low at 2.4% for APG777-exposed patients [9] Group 3: Future Developments - APEX Part B is set to test higher doses of APG777, with readout expected in mid-2026, and the initiation of a Phase 3 trial planned for 2026 [1][3][6] - The company is also conducting a Phase 1b head-to-head trial of APG279 against DUPIXENT, with results anticipated in the second half of 2026 [1][3]

Core Insights - APG777 has shown significant efficacy in treating moderate-to-severe atopic dermatitis, achieving a 71.0% reduction in EASI from baseline at Week 16, surpassing the placebo group which had a 33.8% reduction [1][9] - The drug demonstrated an EASI-75 response rate of 66.9%, the highest for any biologic in a global study, with a placebo-adjusted rate of 42.5% [1][3][9] - A favorable safety profile was observed, with serious treatment-emergent adverse events being rare at 1.2% compared to 2.4% in the placebo group [9] Clinical Trial Results - The Phase 2 APEX trial Part A enrolled 123 adult patients, randomized 2:1 to receive APG777 or placebo, with a dosing regimen of 720mg at Weeks 0 and 2, followed by 360mg at Weeks 4 and 12 [4][9] - Key secondary endpoints included EASI-90 and Validated Investigator Global Assessment (IGA) 0/1, with EASI-90 achieving 33.9% compared to 14.7% in placebo (p < 0.05) and vIGA 0/1 at 34.9% compared to 17.3% in placebo (p < 0.05) [9] - Rapid onset of itch relief was noted, with a 50.7% reduction in Itch NRS from baseline by Week 1 compared to 23.2% in the placebo group (p < 0.01) [9] Future Developments - APEX Part B is set to test higher doses of APG777, with results expected in mid-2026, while the maintenance phase readout from Part A is anticipated in the first half of 2026 [1][6] - The company is also conducting a Phase 1b trial of APG279, a combination therapy, with readout expected in the second half of 2026 [2][3] Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology markets, including atopic dermatitis [2][8] - The company aims to optimize efficacy and dosing through advanced antibody engineering, targeting well-established mechanisms of action [8][10]

Company Overview - Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology (I&I) markets, targeting conditions such as atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), and chronic obstructive pulmonary disease (COPD) [3] - The company aims to overcome limitations of existing therapies by utilizing advanced antibody engineering to optimize properties like half-life, with a focus on achieving best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies [3] Upcoming Events - Apogee Therapeutics will report Part A 16-week data from the Phase 2 APEX trial of its lead program APG777 on July 7, 2025, followed by a conference call and webcast at 8:00 a.m. ET to discuss the results [1][2] Product Pipeline - APG777 is the most advanced program of Apogee, initially developed for the treatment of atopic dermatitis, which is identified as the largest and one of the least penetrated I&I markets [3] - The company has four validated targets in its portfolio, indicating a broad pipeline and depth of expertise aimed at delivering value and meaningful benefits to patients underserved by current standard care [3]

今日，安踏集团第三届创新奖颁奖典礼在厦门举行，总奖金超百万。此次共有21项创新成果受到表彰， 包括8项鞋服产品创新、7项技术创新及6项模式创新。这些获奖项目不仅为集团旗下各品牌业务发展注 入了强劲动力，更通过打造多个市场爆款产品显著提升了品牌价值与消费者心智，为各品牌的长期增长 奠定了坚实基础。 未来五年创新投入200亿 安踏集团过去十年累计创新相关投入达200亿元，并预计在未来五年进一步投入200亿元用于自主创新研 发。集团累计申请专利5830件，居行业首位，已经成为全球行业首个ISO56001国际创新管理体系认证 的企业，并被正式评定为创新管理成熟度四级（完整级），该等级是目前企业获得的最高等级认证。 安踏集团在2021年宣布了"1+4+5创新战略"，以达成在科技创新领域世界领先的目标愿景。目前已构建 全球7大设计研发中心、70多所高校及科研机构、250多位专家、800多家供应商共同参与的"全球开放式 创新生态网络"。集团成立博士后科研工作站，吸引大量顶尖人才，在运动科学、新材料、新技术、新 工艺等领域展开前瞻型科研探索；与清华大学等国内著名高校达成合作，通过校企合作，诞生多项自研 技术成果，如安踏膜、柔 ...

SAN FRANCISCO and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 10:30 a.m. E.T. A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About Apogee Apogee Therapeutics is a clinical-stage biotechnology company advancin ...

证券研究报告 | 行业专题研究 gszqdatemark 2025 05 20 年 月 日 纺织服饰 新消费趋势下，如何寻找服饰板块投资机会？ 新的消费市场偏好和逻辑：实用主义和"悦己"。1）国内消费力增长有限，同时消费者对传 统营销与大众品牌逐渐祛魅，决策选择更加理性，带来"实用主义"的盛行。2）年轻群体出 于悦己需求，偏好体验式互动式消费，热爱个性化、多元化品类，同时追求舒适性与自然。 服饰珠宝赛道新趋势明显，户外/古法金等品类盛行，新渠道业态产生。1）产品端：多样化 需求得以体现。①在服装板块，居民对户外运动以及跑步参与度不断提升，相关鞋服产品消 费规模扩张。同时以马面裙、洞洞鞋为代表的细分品类在年轻消费者"悦己"、"实用主义" 消费观念下，市场规模也处于扩张过程，2024Q4 洞洞鞋头部公司 crocs 在中国市场的营收 同比增长 64%。②在珠宝板块，古法金需求火热，中国古法黄金珠宝市场规模从 2018 年的 130 亿元增长至 2023 年的 1573 亿元，中长期我们认为随着年轻消费群体成为主流，同时 古法金饰品设计优异，市场规模有望保持快速增长态势。2）渠道端：全渠道融合加速、体验 升级。线上 ...

Investment Rating - The report maintains a "Buy" rating for Anta Sports [4][5][13] Core Viewpoints - Anta Sports is focusing on enhancing its product lines, particularly the Kyrie series, while also introducing the PG7 technology aimed at the general public for running shoes [1][2] - The company is expected to benefit from the growing sports and outdoor market, with projected revenues of RMB 78.6 billion, RMB 88.3 billion, and RMB 101.1 billion for the years 2025 to 2027 [4] - The report highlights the innovative features of the PG7 technology, including a G value of 7.8 for shock absorption and a design tailored for East Asian foot shapes, which has led to global sales of over 3 million pairs by March 2025 [2][3] Summary by Sections Product Development - Anta has launched the Kyrie 2, featuring high-quality leather, nitrogen technology insoles, and a lightweight exoskeleton material for enhanced performance [1] - The PG7 technology, designed for the general public, emphasizes shock absorption and comfort, with a price point around RMB 300, making it accessible [2][3] Financial Projections - The report forecasts net profits of RMB 13.5 billion, RMB 15.7 billion, and RMB 17.9 billion for the years 2025 to 2027, with EPS expected to be RMB 4.82, RMB 5.60, and RMB 6.39 respectively [4] - The PE ratios are projected to be 18, 15, and 13 for the same period [4] Market Position - Anta Sports is positioned as a leading player in the non-essential consumer goods sector, particularly in textiles and apparel, benefiting from a robust brand matrix [4][5]